Samrat Pharmachem Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Samrat Pharmachem Ltd is ₹ 212.35 as of 05 May 15:30 . The P/E Ratio of Samrat Pharmachem Ltd changed from 7.9 on March 2021 to 13.6 on March 2025 . This represents a CAGR of 11.48% over 5 yearsThe P/E Ratio of Vaishali Pharma Ltd changed from 32.9 on March 2021 to 209.7 on March 2025 . This represents a CAGR of 44.84% over 5 years The Market Cap of Samrat Pharmachem Ltd changed from ₹ 42.02 crore on March 2021 to ₹ 96.63 crore on March 2025 . This represents a CAGR of 18.12% over 5 yearsThe Market Cap of Vaishali Pharma Ltd changed from ₹ 171.9 crore on March 2021 to ₹ 134.85 crore on March 2025 . This represents a CAGR of -4.74% over 5 years The Revenue of Samrat Pharmachem Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Samrat Pharmachem Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Samrat Pharmachem Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Samrat Pharmachem Ltd changed from 1.8 % on March 2022 to 4.35 % on March 2025 . This represents a CAGR of 24.68% over 4 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Samrat Pharmachem Ltd

Samrat Pharmachem Limited was incorporated on June 16, 1992 at Ankleshwar in Gujarat led by the Promoters, Mr. Lalit Mehta & Mr. Rajesh Mehta.
Since then, it envisioned to focus on lodine Derivatives as their core products.
The Company's principal activities are manufacturing and selling chemicals.
Company is a producer of pharmaceutical chemicals.
The intermediates produced are used in pharmaceutical and chemical industries.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Samrat Pharmachem Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Samrat Pharmachem Ltd or Vaishali Pharma Ltd?

Market cap of Samrat Pharmachem Ltd is 65 Cr while Market cap of Vaishali Pharma Ltd is 96 Cr

What are the key factors driving the stock performance of Samrat Pharmachem Ltd and Vaishali Pharma Ltd?

The stock performance of Samrat Pharmachem Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Samrat Pharmachem Ltd and Vaishali Pharma Ltd?

As of May 5, 2026, the Samrat Pharmachem Ltd stock price is INR ₹213.3. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.43.

How do dividend payouts of Samrat Pharmachem Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Samrat Pharmachem Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.